Patricia Anacio for ALS Today writes: BrainStorm Cell Therapeutics announced that the Phase 3 clinical trial of its cell therapy candidate NurOwn in 200 amyotrophic lateral sclerosis (ALS) patients is fully enrolled and treatment is underway. The randomized,...
REDWOOD CITY, Calif., Oct. 11, 2019 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc (Nasdaq: MNLO), a late-stage biopharmaceutical company, presented results from its successful Phase 2 clinical trial of serlopitant for the treatment of pruritis in patients with...
NEW YORK, Oct. 11, 2019 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it has fully enrolled the 200-patient Phase 3 clinical trial...
MENLO PARK, Calif., Oct. 10, 2019 (GLOBE NEWSWIRE) — Geron Corporation (GERN) today announced that the first patient has been dosed in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic...
RALEIGH, N.C., Oct. 10, 2019 /PRNewswire/ — Bryn Pharma, LLC (“Bryn”) is a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis. Bryn has developed an epinephrine nasal spray, a...
Email
Text